查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1618624

黑色素瘤治療藥物市場：按類型、產品和分銷管道分類 - 全球預測 2025-2030

Melanoma Drug Market by Type (Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma), Product (Adjuvant Therapy, Biochemotherapy, Chemotherapy Drugs), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年黑色素瘤治療市場價值為54億美元，預計2024年將達到58.1億美元，複合年成長率為8.32%，預計到2030年將達到94.5億美元。

黑色素瘤治療市場包括一系列用於檢測、預防和治療黑色素瘤的治療方法，黑色素瘤是一種主要由黑色素產生細胞產生的嚴重皮膚癌。由於長期紫外線照射和遺傳傾向等因素，全球黑色素瘤發生率不斷增加，因此需要有效的治療方法，因此需要黑色素瘤治療。其應用涵蓋個人化醫療、免疫治療、標靶治療和化療，為醫院、診所、癌症研究機構和專科醫療中心等主要最終用戶提供服務。關鍵的成長要素包括生物技術的進步、研發投資的增加、政府促進癌症早期檢測的努力以及黑色素瘤盛行率的上升推動了對創新藥物的需求。最新的機會在於開發個人化免疫療法和聯合治療解決抗藥性並提高現有療法的有效性。為了抓住這些機會，將透過投資尖端研究、與生物技術公司合作以及在藥物發現中利用人工智慧來推動成長。然而，高昂的治療成本、嚴格的監管要求和潛在的副作用等挑戰限制了其採用。此外，學名藥的競爭和早期診斷的挑戰（需要明確的治療方法）也限制了市場的成長。開拓這個市場可能會圍繞著開發副作用較少的藥物、使用 CRISPR 基因編輯技術以及創建針對不同患者情況的綜合組合方案。研究可以進一步探索奈米技術與生物製藥的融合。市場動態本質上是動態的，受到科學進步和對有效解決方案的迫切需求的推動，而成長需要策略性地應對獨特的挑戰和監管環境，這提供了許多途徑。

主要市場統計
基準年[2023] 54億美元
預計年份 [2024] 58.1億美元
預測年份 [2030] 94.5億美元
複合年成長率（%） 8.32%

市場動態：揭示快速發展的黑色素瘤藥物市場的關鍵市場洞察

供需的動態交互作用正在改變黑色素瘤藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球黑色素瘤和其他皮膚癌盛行率不斷上升
    • 政府增加醫療保健支出
    • 癌症領域生物相似藥開發活性化
  • 市場限制因素
    • 與藥物開發和治療相關的高成本
  • 市場機會
    • 對減少副作用和高效率的標靶治療的需求不斷增加
    • 持續研發努力推出有效藥物
  • 市場挑戰
    • 嚴格的監管政策和漫長的核准流程

波特的五力：駕馭黑色素瘤藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對黑色素瘤藥物市場的影響

外部宏觀環境因素在塑造黑色素瘤治療藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解黑色素瘤治療藥物市場的競爭狀況

對黑色素瘤治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣黑色素瘤治療市場供應商的績效評估

FPNV 定位矩陣是評估黑色素瘤治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪黑色素瘤治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對黑色素瘤治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球黑色素瘤和其他皮膚癌的發生率不斷上升
      • 政府增加醫療保健支出
      • 推動腫瘤領域生物相似藥的發展
    • 抑制因素
      • 藥物開發和治療成本高昂
    • 機會
      • 對副作用更少、效率更高的標靶治療的需求不斷增加
      • 繼續進行旨在推出有效藥物的研究和開發活動
    • 任務
      • 嚴格的監管政策和漫長的核准流程
  • 市場區隔分析
    • 類型：肢端惡性黑色素瘤和惡性黑色素瘤對非侵入性治療方法的需求不斷增加
    • 產品：對治療惡性黑色素瘤疾病進展和基因突變的下一代藥物的需求增加
    • 分銷管道：由於便利和遠端醫療支持，對線上管道的需求不斷成長
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章黑色素瘤治療藥物市場：依類型

  • 肢端雀斑樣黑色素瘤
  • 惡性雀斑
  • 結節性黑色素瘤
  • 表淺黑色素瘤

第7章黑色素瘤治療藥物市場：依產品

  • 輔助性治療
  • 化療
  • 化療藥物
    • Dacarbazine(DTIC-Dome)
    • Temozolomide（Temodar）
  • 免疫治療藥物
    • 查核點抑制劑
    • CTLA-4抑制劑
  • 溶瘤病毒療法
  • 標靶治療
    • BRAF抑制劑
    • MEK抑制劑

第8章黑色素瘤治療藥物市場：按分銷管道

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第9章北美和南美黑色素瘤藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區黑色素瘤藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲黑色素瘤藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Moderna 和 Merck 報告稱，與 KEYTRUDA 相比，mRNA-4157 (V940) 和 KEYTRUDA (Pembrolizumab) 的組合在高風險 III/IV 期惡性黑色素瘤患者完全切除後 3 年顯示無復發生存率持續改善。了無遠處轉移的生存。
    • Sun Pharma 和 Philogen 的黑色素瘤治療在 3 期試驗中顯示出有希望的結果
    • 美國食品藥物管理局核准Opdivo （nivolumab）作為合格的IIB 期或 IIC 期惡性完全切除患者的輔助治療
  • 戰略分析和建議

公司名單

  • AB Science
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CK Life Sciences Int'l.,（Holdings）Inc.
  • Clinigen Group PLC
  • Eli Lilly and Company
  • Enzon Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Immunocore Limited
  • Merck KGaA
  • Moderna, Inc
  • Novartis AG
  • Pfizer, Inc.
  • Philogen SpA
  • Regeneron Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Limited
  • Taj Pharmaceuticals Limited
  • Takeda Pharmaceutical Company Limited
  • Wellona Pharma
Product Code: MRR-0363DFE03682

The Melanoma Drug Market was valued at USD 5.40 billion in 2023, expected to reach USD 5.81 billion in 2024, and is projected to grow at a CAGR of 8.32%, to USD 9.45 billion by 2030.

The Melanoma Drug market encompasses a range of therapeutic treatments used primarily for the detection, prevention, and therapy of melanoma, a severe form of skin cancer arising from melanin-producing cells. The necessity of melanoma drugs stems from increasing global melanoma incidences, heightened by factors such as prolonged UV exposure, and genetic predisposition, thereby necessitating effective treatments. Applications extend to personalized medicine, immunotherapy, targeted therapy, and chemotherapy, serving primary end-users such as hospitals, clinics, cancer research institutes, and specialty care centers. Key growth influencers include advancements in biotechnology, increased R&D investments, government initiatives promoting early cancer detection, and a rising prevalence of melanoma enhancing the demand for innovative drugs. Latest opportunities lie in the development of personalized immunotherapies and combination therapies that address resistance and improve the efficacy of existing treatments. To seize these opportunities, investing in cutting-edge research, collaborations with biotech firms, and leveraging AI in drug discovery can drive growth. However, challenges include the high cost of treatment, stringent regulatory requirements, and potential side effects limiting adoption. Market growth is also constrained by competition from generic drugs and the challenge of early-stage diagnosis requiring distinct treatment approaches. Innovations in this market could pivot around developing drugs with lower side effects, utilizing CRISPR gene-editing technology, and creating comprehensive multi-drug regimens that cater to diverse patient profiles. Research can further explore the integration of nanotechnology and biopharmaceuticals. The melanoma drug market is dynamic by nature, driven by both scientific progress and an urgent need for effective solutions, presenting numerous avenues for growth while requiring strategic navigation of inherent challenges and regulatory landscapes.

KEY MARKET STATISTICS
Base Year [2023] USD 5.40 billion
Estimated Year [2024] USD 5.81 billion
Forecast Year [2030] USD 9.45 billion
CAGR (%) 8.32%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Melanoma Drug Market

The Melanoma Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of melanoma and other skin cancers globally
    • Increase in government expenditures on healthcare
    • Elevated development of biosimilar in oncology arena
  • Market Restraints
    • High costs associated with drug development and treatment
  • Market Opportunities
    • Emerging need for targeted therapy owing to reduced side effects and higher efficiency
    • Ongoing research and development activities to introduce effective drugs
  • Market Challenges
    • Stringent regulatory policies and lengthy approval process

Porter's Five Forces: A Strategic Tool for Navigating the Melanoma Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Melanoma Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Melanoma Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Melanoma Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Melanoma Drug Market

A detailed market share analysis in the Melanoma Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Melanoma Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Melanoma Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Melanoma Drug Market

A strategic analysis of the Melanoma Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Melanoma Drug Market, highlighting leading vendors and their innovative profiles. These include AB Science, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, CK Life Sciences Int'l., (Holdings) Inc., Clinigen Group PLC, Eli Lilly and Company, Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Immunocore Limited, Merck KGaA, Moderna, Inc, Novartis AG, Pfizer, Inc., Philogen S.p.A., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Melanoma Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma, and Superficial Spreading Melanoma.
  • Based on Product, market is studied across Adjuvant Therapy, Biochemotherapy, Chemotherapy Drugs, Immunotherapy Drugs, Oncolytic Virus Therapy, and Targeted Therapy Drugs. The Chemotherapy Drugs is further studied across Dacarbazine (DTIC-Dome) and Temozolomide (Temodar). The Immunotherapy Drugs is further studied across Checkpoint Inhibitors and CTLA-4 Inhibitors. The Targeted Therapy Drugs is further studied across BRAF Inhibitors and MEK Inhibitors.
  • Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of melanoma and other skin cancers globally
      • 5.1.1.2. Increase in government expenditures on healthcare
      • 5.1.1.3. Elevated development of biosimilar in oncology arena
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with drug development and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging need for targeted therapy owing to reduced side effects and higher efficiency
      • 5.1.3.2. Ongoing research and development activities to introduce effective drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory policies and lengthy approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising demand of non-invasive therapies across acral lentiginous melanoma and lentigo maligna melanoma
    • 5.2.2. Product: Boost in demand for next generation drugs to treat disease progression and genetic mutations in Melanoma
    • 5.2.3. Distribution Channel: Rising demand of online channel due to convenience and telehealth support
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Melanoma Drug Market, by Type

  • 6.1. Introduction
  • 6.2. Acral Lentiginous Melanoma
  • 6.3. Lentigo Maligna Melanoma
  • 6.4. Nodular Melanoma
  • 6.5. Superficial Spreading Melanoma

7. Melanoma Drug Market, by Product

  • 7.1. Introduction
  • 7.2. Adjuvant Therapy
  • 7.3. Biochemotherapy
  • 7.4. Chemotherapy Drugs
    • 7.4.1. Dacarbazine (DTIC-Dome)
    • 7.4.2. Temozolomide (Temodar)
  • 7.5. Immunotherapy Drugs
    • 7.5.1. Checkpoint Inhibitors
    • 7.5.2. CTLA-4 Inhibitors
  • 7.6. Oncolytic Virus Therapy
  • 7.7. Targeted Therapy Drugs
    • 7.7.1. BRAF Inhibitors
    • 7.7.2. MEK Inhibitors

8. Melanoma Drug Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Retail Pharmacies
  • 8.3. Online

9. Americas Melanoma Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Melanoma Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Melanoma Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
    • 12.3.2. Sun Pharma and Philogen's Melanoma Drug Shows Promising Outcome in Phase 3 Trial
    • 12.3.3. U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AB Science
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Bristol-Myers Squibb Company
  • 6. CK Life Sciences Int'l., (Holdings) Inc.
  • 7. Clinigen Group PLC
  • 8. Eli Lilly and Company
  • 9. Enzon Pharmaceuticals, Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Genentech, Inc.
  • 12. GlaxoSmithKline PLC
  • 13. Hikma Pharmaceuticals PLC
  • 14. Immunocore Limited
  • 15. Merck KGaA
  • 16. Moderna, Inc
  • 17. Novartis AG
  • 18. Pfizer, Inc.
  • 19. Philogen S.p.A.
  • 20. Regeneron Pharmaceuticals Inc.
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Taj Pharmaceuticals Limited
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Wellona Pharma

LIST OF FIGURES

  • FIGURE 1. MELANOMA DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. MELANOMA DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MELANOMA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MELANOMA DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MELANOMA DRUG MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MELANOMA DRUG MARKET SIZE, BY BIOCHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MELANOMA DRUG MARKET SIZE, BY DACARBAZINE (DTIC-DOME), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MELANOMA DRUG MARKET SIZE, BY TEMOZOLOMIDE (TEMODAR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 149. TAIWAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 156. THAILAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 163. VIETNAM MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 178. DENMARK MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 185. EGYPT MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 192. FINLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 199. FRANCE MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 206. GERMANY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 213. ISRAEL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 220. ITALY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 234. NIGERIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 241. NORWAY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 248. POLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 255. QATAR MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 262. RUSSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 276. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 283. SPAIN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 290. SWEDEN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 297. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 304. TURKEY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. TURKEY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 311. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 325. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 326. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023